Glucotrack Clears Key Milestone to Commercialize Its Implantable CGM

50 second read

By Karen Roman

Glucotrack, Inc. (Nasdaq: GCTK) said the US Patent and Trademark Office issued a Notice of Allowance for a patent application which expands the intellectual property protecting the company’s continuous blood glucose monitoring (CBGM) platform as it moves towards commercialization.

This adds to the company’s three CBGM patents issued in 2025 and includes electrode configurations, lead-based sensing structures, and associated implantation methods for continuous glucose measurement, the Glucotrack stated.

The Cancer Therapy Strategy VERAXA Is Betting the Company On

“Continuing to build our intellectual property is fundamental to our strategy as we advance the fully implantable system through clinical testing and toward commercialization,” said Paul V. Goode, PhD, Glucotrack President and CEO.